Mereo Biopharma Group Plc (MREO)
NASDAQ:MREO
Want to see MREO full AI Analyst Report?
MREO Stock Chart & Stats
$0.34
-$0.02(-0.40%)
At close: 4:00 PM EST
$0.34
-$0.02(-0.40%)
Day’s Range― - ―
52-Week Range$0.20 - $3.05
Previous CloseN/A
Volume219.93K
Average Volume (3M)1.50M
Market Cap
$43.98M
Enterprise Value$3.33M
Total Cash (Recent Filing)$40.99M
Total Debt (Recent Filing)$202.00K
Price to Earnings (P/E)―
Beta1.19
Next Earnings
May 20, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding159,615,770
10 Day Avg. Volume1,831,691
30 Day Avg. Volume1,496,844
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)1.62
Price to Sales (P/S)132.86
P/FCF Ratio-2.14
Enterprise Value/Market Cap0.08
Enterprise Value/Revenue6.66
Enterprise Value/Gross Profit9.09
Enterprise Value/Ebitda-0.08
Forecast
1Y Price Target
$2.33Price Target Upside586.27% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.01
Revenue Forecast (FY)$18.44M
Bulls Say, Bears Say
Bulls Say
Clinical EfficacySignificant increases in bone mineral density, particularly in the lumbar spine, demonstrate biological activity of the treatment and suggest potential to strengthen bone health.
Partnerships And PipelineOrphan designation for a lung candidate and active partnering discussions, along with a partner planning to advance another candidate into phase two, enhance prospects for external support and future commercialization.
Patient-reported OutcomesPatient-reported data showed reductions in bone pain and improvements in daily functioning for pediatric and teen patients, indicating tangible quality-of-life benefits.
Bears Say
Clinical Trial InterpretationA strong placebo response and increased activity among treated patients complicated trial results, obscuring whether the treatment truly reduces fracture incidence.
Funding RiskA limited cash runway increases the likelihood that the company will need additional funding or partnerships to support further development and any potential product launch.
Regulatory UncertaintyRegulatory prospects are unclear because the main trials did not demonstrate the expected reduction in fracture rates, leaving approval pathways unresolved.
Mereo Biopharma Group Plc News
MREO FAQ
What was Mereo Biopharma Group Plc’s price range in the past 12 months?
Mereo Biopharma Group Plc lowest stock price was $0.20 and its highest was $3.05 in the past 12 months.
What is Mereo Biopharma Group Plc’s market cap?
Mereo Biopharma Group Plc’s market cap is $43.98M.
When is Mereo Biopharma Group Plc’s upcoming earnings report date?
Mereo Biopharma Group Plc’s upcoming earnings report date is May 20, 2026 which is in 19 days.
How were Mereo Biopharma Group Plc’s earnings last quarter?
Mereo Biopharma Group Plc released its earnings results on Mar 19, 2026. The company reported -$0.01 earnings per share for the quarter, beating the consensus estimate of -$0.013 by $0.003.
Is Mereo Biopharma Group Plc overvalued?
According to Wall Street analysts Mereo Biopharma Group Plc’s price is currently Undervalued.
Does Mereo Biopharma Group Plc pay dividends?
Mereo Biopharma Group Plc does not currently pay dividends.
What is Mereo Biopharma Group Plc’s EPS estimate?
Mereo Biopharma Group Plc’s EPS estimate is >-0.01.
How many shares outstanding does Mereo Biopharma Group Plc have?
Mereo Biopharma Group Plc has 159,615,770 shares outstanding.
What happened to Mereo Biopharma Group Plc’s price movement after its last earnings report?
Mereo Biopharma Group Plc reported an EPS of -$0.01 in its last earnings report, beating expectations of -$0.013. Following the earnings report the stock price went up 2.564%.
Which hedge fund is a major shareholder of Mereo Biopharma Group Plc?
Currently, no hedge funds are holding shares in MREO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mereo Biopharma Group Plc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.33 (586.27% Upside)
$2.33 (586.27% Upside)
Blogger Sentiment
Bullish
MREO Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 517.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.1%
Last 30 Days ▼ 1.6%
Last 30 Days ▼ 1.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-85.39%
12-Months-Change
Fundamentals
Return on Equity
-83.02%
Trailing 12-Months
Asset Growth
-39.89%
Trailing 12-Months
Company Description
Mereo Biopharma Group Plc
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.
MREO Stock 12 Month Forecast
Average Price Target
$2.33
▲(586.27% Upside)
Technical Analysis
Ownership Overview
0.81%
Insiders
0.09% Mutual Funds
0.07% Other Institutional Investors
98.71% Public Companies and
Individual Investors